Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177710 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study
A Phase 3 study of Lung Transplantation and Fungal Infections, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00177710 is a Phase 3 study of Lung Transplantation and Fungal Infections that has completed, run by University of Pittsburgh. The registered enrollment target is 48 participants, below the 332-participant average among 12 other Lung Transplantation trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00177710, a Phase 3 study of Lung Transplantation and Fungal Infections, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the steady state concentrations of inhaled liposomal amphotericin B (Ambisome®) in lung transplant recipients via aerosolized nebulization.
Conditions Studied
Interventions
- DRUG Amphotericin B
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177710
The ClinicalTrials.gov registry entry for NCT00177710 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 12 other Lung Transplantation trials with a reported enrollment target (86% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Amphotericin B is the first listed.
NCT00177710 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00177710 about?
NCT00177710 is a clinical study titled "Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study". The purpose of this study is to determine the steady state concentrations of inhaled liposomal amphotericin B (Ambisome®) in lung transplant recipients via aerosolized nebulization.
What is the current status of trial NCT00177710?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2006-01. Estimated completion is 2007-12.
What conditions does trial NCT00177710 study?
This clinical trial studies the following conditions: Lung Transplantation, Fungal Infections.
What interventions are being tested in trial NCT00177710?
The interventions under investigation include: Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00177710?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177710 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
RECRUITING
-
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
RECRUITING · Phase 2
-
Trifecta-Lung cfDNA-MMDx Study
RECRUITING
-
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
RECRUITING
-
Transplanting Lungs From Uncontrolled Donation After Circulatory Death
RECRUITING · NA
-
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.